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Sir,
An emerging strategy for refractory adult solid malignancies is
to manage cancer as a chronic but stable disease state, where the
total tumour burden is kept at the lowest possible level. One of the
most likely strategies to achieve this would seem to be the targeting
of neoangiogenesis. Recently, a new paradigm has emerged based
on the targeting of tumour vasculature rather than tumour
parenchyma with low-dose but long-term, continuous, chemother-
apy using classical cytotoxic agents. The term ‘metronomic dosing’
was first used by Hanahan et al (2000). For further details on
metronomic chemotherapy (MC), see the recent, extensive, review
by Kerbel and Kamen (2004).
While intuitively there should be no disagreement with what
constitutes a metronomic schedule, our major concern relates to
the dosing levels. The starting point for conventional dosing is
empirical, for example, 1
10th of the LD50 of a preclinical, animal-
based, toxicity study. From then on, the dose for human use is
based on the Phase I study. The starting dose for MC is equally
empirical with the major proponents commencing clinical or
preclinical trials at 10–33% of conventional doses; no further
effort to define this dose is made! The historical variability of
clinical response to chemotherapy and the concern about intertrial
reproducibility of results will be compounded by the lack of dose
uniformity. It is hard enough correlating responses among
different conventional dosing schemes, for example, taxanes in
ovarian cancer; it will be even more difficult if the dosing scheme
has little rhyme or reason justifying its selection. Given the large
number of drugs with potential antiangiogenic properties when
given metronomically, the further development of combination
treatments will become even more contentious. We think that a
strategy to deal with this problem is necessary given that extreme
empiricism could breed scepticism which in turn would signifi-
cantly delay progress in this field. Fortunately, we would suggest
that there are already enough data to allow for a principled
approach to metronomic dosing.
Reflecting conventional design, the metronomic Phase I trial
methodology that we propose is based on the following principles:
(a) Choice of initial dose and dosing schedule.
(b) Dose ranging.
(c) End points.
(a) While conventional dosing schedules often have bewildering
complexity, only two schedules would be relevant for
metronomic delivery (MetS), and these are daily oral and
continuous infusion schedules. Pharmacokinetic studies of
drug and metabolites given in these continuous schedules
should be undertaken as per the conventional approach. A
logical extension of this is that all new drugs (especially oral
agents) developed should also have a continuous dosing
schedule in their Phase I development portfolio.
(b) We would argue that dose ranging is essential given that there
is very good evidence in vitro that different agents have
varying capacities to inhibit the growth of endothelial cells at
different doses. Work from our laboratory (Figures 1 and 2)
clearly shows that for similar exposure times and conditions,
the effects of an alkylating agent (temozolomide) are different
to those of an antimitotic agent (estramustine) on human
umbilical vein endothelial cell (HUVEC) growth. Furthermore,
even at these low drug doses, we demonstrate a clear dose–
response curve. We would therefore propose that the highest
dose that can be given in a metronomic manner would be
likely to have the greatest effect on the endothelium.
(c) The crux of the matter is defining the ‘dose limit’ related to the
second principle articulated above, that is, the clinical
metronomic dose (MetD). Bone marrow suppression is the
single most potent, clinically preventable, proangiogenic
stimulus related to conventional treatments. Release of
haematopoietic stem cells including endothelial progenitor
cells (CEP) from the bone marrow into the circulation in
response to chemotherapy, cytokine stimulation or irradiation
was first documented more than three decades ago (reviewed
in To et al, 1997). Animal models have verified that CEP
play a major role in tumour neoangiogenesis, and that there
is a major difference in CEP mobilisation for the same
agent (cyclophosphamide) when comparing conventional
and metronomic dosing regimes (Bertollini et al, 2003).
We therefore propose that MetD should be the highest dose
that can be delivered in a metronomic schedule without
causing clinical bone marrow perturbation, assuming
that there are no other dose-limiting toxicities that appear
before bone marrow disruption. Monitoring the full blood
count, although practical, may be insensitive; therefore, *Correspondence: Dr A Maraveyas, E-mail: A.Maraveyas@hull.ac.uk
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activation circulation is likely to produce more useful tools in
the near future.
In conclusion, scheduling of MC is arguably unequivocal;
dosing, however, is poorly defined. We argue that even in the
subclinical dose range, there is a dose–response effect on the
endothelium, and that using an arbitrary 10–33% of the
conventional dose is not always appropriate. Given that bone
marrow suppression is a proangiogenic stimulus, we propose that
the MetD should be the maximum dose that can be delivered in a
metronomic schedule without detectable bone marrow perturba-
tion. Such a rational strategy would allow MC dosing to be derived
via a principled approach.
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Figure 1 Endothelial cell-specific growth inhibition at low doses following 4-day continuous exposure to estramustine. Experiment conducted as
quadruplicates and repeated at least twice. All cells, that is, HUVECs, human fibroblasts, human melanoma and human RCC cells were under passage 6 and
grown as monolayers in 96-well plates and treated with either agent for 4 days, with daily replacement and replenishment of media. Cell proliferation assay
performed via MTS assay with background-subtracted absorbance at 490nm determined hourly for up to 4h. Baseline cell growth¼((cell no. of test at 4
days cell no. of test prior to treatment)/cell no. of test prior to treatment) 100%. The baseline growth of control, untreated, cells (i.e. control) is taken as
100% and growth of treated populations of cells is expressed as % of this control growth (mean7s.e.).
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Figure 2 Endothelial cell-specific growth inhibition at low doses following 4-day continuous exposure to temozolomide. Experiment conducted as
quadruplicates and repeated at least twice. All cells, that is, HUVECs, human fibroblasts, human melanoma and human RCC cells were under passage 6 and
grown as monolayers in 96-well plates and treated with either agent for 4 days, with daily replacement and replenishment of media. Cell proliferation assay
performed via MTS assay with background-subtracted absorbance at 490nm determined hourly for up to 4h. Baseline cell growth¼((cell no. of test at 4
days cell no. of test prior to treatment)/cell no. of test prior to treatment) 100%. The baseline growth of control, untreated, cells (i.e. control) is taken as
100% and growth of treated populations of cells is expressed as % of this control growth (mean7s.e.).
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